Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-07159-9Source: DataRank Database

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study is a research paper published in Breast Cancer Research and Treatment (2023). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 0.37)OA: greenTopics (35)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (17)

Marie Kassapian,Véronique Debien ORCID,Rafael Caparica ORCID,Daniel Eiger ORCID,Urania Dafni ORCID

Live enrichment

PubMed:37938495 OpenAlex:https://openalex.org/W4388492584

National Cancer Institute

Grant: U10CA180821

National Cancer Institute

Grant: U10CA180882

National Cancer Institute

Grant: UG1CA233180

National Cancer Institute

Grant: UG1CA233196

National Cancer Institute

Grant: UG1CA233329

National Cancer Institute

Grant: UG1CA232760

National Cancer Institute

Grant: U10CA180863

Canadian Cancer Society

Grant: 704970

National Institutes of Health

Grant: 5UG1CA233196-03

Johns Hopkins University NCTN Lead Academic Site Program

National Institutes of Health

Grant: 5UG1CA233180-02

NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

National Institutes of Health

Grant: 5UG1CA233329-06

UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1

National Institutes of Health

Grant: 5U10CA180863-08

Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

National Institutes of Health

Grant: 5U10CA180882-02

Statistics and Data Center for the Alliance for Clinical Trials in Oncology

National Institutes of Health

Grant: 3UG1CA232760-06S1

NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension)

National Institutes of Health

Grant: 3U10CA180821-02S2

Alliance for Clinical Trials in Oncology Operations Center

FWCI

0.37

Citation Percentile

0.6%

Citation Trend

2024

2025

greenLicense: Springer Nature TDM

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11052564/pdf/nihms-1984155.pdf

publisherhttps://link.springer.com/content/pdf/10.1007/s10549-023-07159-9.pdf

publisherhttps://link.springer.com/article/10.1007/s10549-023-07159-9/fulltext.html

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11052564

Fields of Study

Erythropoietin and Anemia TreatmentNanoparticle-Based Drug DeliveryBreast Cancer Treatment Studies03 medical and health sciences0302 clinical medicine

MeSH Terms

TrastuzumabAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErythropoiesisFemaleHumansMiddle AgedTreatment OutcomeChemotherapy, AdjuvantDisease-Free SurvivalReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases

Keywords

MedicineBreast cancerErythropoiesisAdjuvantOncologyCancerInternal medicineAnemiaTreatment OutcomeChemotherapy, AdjuvantAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleBreast NeoplasmsMiddle AgedTrastuzumabErb-b2 Receptor Tyrosine KinasesDisease-Free Survival

Sustainable Development Goals

SDG 0: Good health and well-being